Chart for preparation of dilutions of alpha-adrenergic agonists for intracavernous use in treatment of priapism.
Treatment of priapism with intracavernous alpha-adrenergic agonist vasoconstrictor agents is well accepted, particularly for patients with priapism secondary to intracavernous injections of papaverine, phentolamine and/or prostaglandin E1. Although many alpha-adrenergic agonists are commercially available, phenylephrine is preferred because it has potent and selective alpha 1-adrenergic stimulatory properties, which can decrease arteriolar flow to the cavernous sinusoids, and no beta 1-stimulatory effect, which could cause arrhythmias and angina in susceptible patients. Before intracavernous injection or irrigation an alpha-adrenergic agonist must be diluted. However, no readily available reference source lists this information. Therefore, we prepared a chart for extemporaneous preparation of dilutions of alpha-adrenergic agonists for intermittent injection or irrigation.
Lee
M
M
Department of Urology, University of Illinois Hospital, Chicago.
Cannon
B
B
Sharifi
R
R
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008297:Male; D010208:Papaverine / Q000009:adverse effects; D010646:Phentolamine / Q000009:adverse effects; D011317:Priapism / Q000139:chemically induced / Q000188:drug therapy*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage
D000316:Adrenergic alpha-Agonists; D014662:Vasoconstrictor Agents; D010208:Papaverine; D010646:Phentolamine